Patents by Inventor Yutaka Kanda
Yutaka Kanda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040110282Abstract: A cell in which the activity of a protein relating to transport of an intracellular sugar nucleotide, GDP-fucose, to the Golgi body is more decreased or deleted than its parent cell; a process for producing an antibody composition using the cell; a transgenic non-human animal or plant or the progenies thereof, in which genome is modified so as to have a decreased or deleted activity of a protein relating to transport of an intracellular sugar nucleotide, GDP-fucose, to the Golgi body; a process for producing an antibody composition from the animal or plant; and a medicament comprising the antibody composition.Type: ApplicationFiled: April 9, 2003Publication date: June 10, 2004Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Yutaka Kanda, Mitsuo Satoh, Katsuhiro Mori
-
Publication number: 20040101936Abstract: According to the present invention, 22,23-dihydroavermectin B1a, which is useful as a medicine, a veterinary drug, and a pesticide, can be directly fermented and produced. This can obviate the need for the complicated and difficult conventional processes for purifying avermectin B1a at an industrial level and for chemically modifying avermectin B1a and can significantly decrease cost and time required in the industrial production of 22,34-dihydroavermectin B1a. The production of the formulation containing only 22,23-dihydroavermectin B1a, which is highly effective as a medicine, is also realized.Type: ApplicationFiled: October 29, 2003Publication date: May 27, 2004Inventors: Hirofumi Endo, Hiroyuki Yamaguchi, Yutaka Kanda, Shinichi Hashimoto, Satoshi Omura, Haruo Ikeda
-
Publication number: 20030181722Abstract: Compounds having immunosuppressive activity, cell growth inhibitory activity, anti-tumor activity, etc.Type: ApplicationFiled: November 7, 2002Publication date: September 25, 2003Applicant: Kyowa Hakko Kogyo Co., Ltd.Inventors: Tsutomu Akama, Hiroyuki Nagata, Atsuhiro Hasegawa, Harumi Ue, Isami Takahashi, Yutaka Saitoh, Kenichi Mochida, Shun-Ichi Ikeda, Yutaka Kanda
-
Patent number: 6613774Abstract: LK6-A derivatives which have immmunosuppressive activity, cell growth inhibitory activity, anti-tumor activity, etc. and which are represented by general formula (I): as defined herein, and pharmaceutically acceptable salts thereof.Type: GrantFiled: January 2, 2001Date of Patent: September 2, 2003Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Tsutomu Akama, Hiroyuki Nagata, Atsuhiro Hasegawa, Harumi Ue, Isami Takahashi, Yutaka Saitoh, Kenichi Mochida, Shun-ichi Ikeda, Yutaka Kanda
-
Publication number: 20030115614Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: ApplicationFiled: October 9, 2001Publication date: June 19, 2003Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
-
Patent number: 6548536Abstract: Agents for inducing apoptosis comprising a tetrocarcin derivative represented by the following formula (I) or a salt thereof as an active ingredient (---- represents a single bond or a double bond; j and k represent 0 or 1; R1 to R3, R7 to R10 and R14 represent a hydrogen atom, a lower alkyl group and the like; R4, R11, R12, R13 and R15 to R18 represent a hydrogen atom, a hydroxyl group, a lower alkyl group and the like; R5 and R6 represents a hydrogen atom, a hydroxyl group, a lower alkyl group, a group represented by the following formula (B) (R32 represents a formyl group and the like, R33 to R35 represent a hydrogen atom, a hydroxyl group, a lower alkyl group and the like); R19 represents a hydroxyl group, a lower alkoxyl group, a lower alkanoyloxy group and the like). The agents are useful as medicaments for preventive and/or therapeutic treatment of diseases resulting from increased expression of Bcl-2 family proteins, for example, cancers, AIDS and the like.Type: GrantFiled: February 27, 2001Date of Patent: April 15, 2003Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Mitsunobu Hara, Takayuki Nakashima, Yutaka Kanda, Masami Hamano, Shun-ichi Ikeda, Yuko Uosaki, Yoko Takata, Junji Kanazawa
-
Patent number: 6518268Abstract: Thiazolidinedione compounds, compositions, and methods of inhibiting telomerase activity in vitro and treatment of telomerase mediated conditions or diseases ex vivo and in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of conditions or diseases mediated by telomerase activity, such as in the treatment of cancer. Also disclosed are novel methods for assaying or screening for inhibitors of telomerase activity.Type: GrantFiled: June 30, 2000Date of Patent: February 11, 2003Assignees: Geron Corporation, Kyowa Hakko Kogyo Co., Ltd.Inventors: Allison C. Chin, Ryan Holcomb, Mieczyslaw A. Piatyszek, Upinder Singh, Richard L. Tolman, Tsutomu Akama, Yutaka Kanda, Akira Asai, Yoshinori Yamashita, Kaori Endo, Hiroyuki Yamaguchi
-
Patent number: 6492392Abstract: The present invention provides 2-piperidone compounds or pharmaceutically acceptable salts thereof, which have a potent activity of inhibiting the proliferation of tumor cells and thus are useful as medicaments, as well as antitumor agents containing these compounds. The 2-piperidone compound is represented by the following formula (I): wherein R1 represents —(CH2)nR1a {wherein n is an integer of from 0 to 5, and R1a represents amino, lower alkylamino, di(lower alkyl)amino, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group}, and R2 and R3 independently represent lower alkyl which may be substituted by lower alkoxycarboyl; lower alkenyl, aralkyl or lower alkynyl which may be substituted by substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; substituted or unsubstituted aryl; or a substituted or unsubstituted heterocyclic group.Type: GrantFiled: January 12, 2000Date of Patent: December 10, 2002Assignees: Kyowa Hakko Kogyo Co., Ltd., Eli Lilly & Co.Inventors: Yutaka Kanda, Rieko Tanaka, Mitsunobu Hara, Jun Eishima, Shiro Akinaga, Tadashi Ashizawa
-
Publication number: 20020137770Abstract: This invention relates to piperidine derivatives having antitumor activity and useful as pharmaceuticals such as an antitumor agent.Type: ApplicationFiled: July 6, 2001Publication date: September 26, 2002Inventors: Shinji Nara, Rieko Nakatsu, Yutaka Kanda, Shiro Akinaga, Mitsunobu Hara, Jun Eishima, Timothy A. Grese, Douglas L. Gernert
-
Patent number: 6407087Abstract: UCF116 derivatives represented by formula (I): wherein Q represents and R represents hydrogen, C(═O)R1a (wherein R1a represents methyl, ethyl, propyl, isopropyl, 2,2-dimethylpropyl, pentyl, alkyl having 6 to 10 carbon atoms, 1-propenyl, isopropenyl, 2-methyl-1-propenyl, substituted or unsubstituted alicyclic alkyl having 3 to 5 carbon atoms, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyloxy, or substituted lower alkyl), C(═X)NHR1b (wherein X represents an oxygen or sulfur atom, and R1b represents substituted or unsubstituted lower alkyl, substituted or unsubstituted alicyclic alkyl, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heterocyclic group), or SO2R1c (wherein R1c represents substituted or unsubstituted lower alkyl, substituted or unsType: GrantFiled: June 27, 2000Date of Patent: June 18, 2002Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Mitsunobu Hara, Shiro Akinaga, Yutaka Kanda, Timothy S. Powers, David A. Johnson
-
Publication number: 20020022598Abstract: Agents for inducing apoptosis comprising a tetrocarcin derivative represented by the following formula (I) or a salt thereof as an active ingredient (- - - - represents a single bond or a double bond; j and k represent 0 or 1; R1 to R3, R7 to R10 and R14 represent a hydrogen atom, a lower alkyl group and the like; R4, R11, R12, R13 and R15 to R18 represent a hydrogen atom, a hydroxyl group, a lower alkyl group and the like; R5 and R6 represents a hydrogen atom, a hydroxyl group, a lower alkyl group, a group represented by the following formula (B) (R32 represents a formyl group and the like, R33 to R35 represent a hydrogen atom, a hydroxyl group, a lower alkyl group and the like); R19 represents a hydroxyl group, a lower alkoxyl group, a lower alkanoyloxy group and the like). The agents are useful as medicaments for preventive and/or therapeutic treatment of diseases resulting from increased expression of Bcl-2 family proteins, for example, cancers, AIDS and the like.Type: ApplicationFiled: February 27, 2001Publication date: February 21, 2002Applicant: KYOWA HAKKO KOGYO CO., LTDInventors: Mitsunobu Hara, Takayuki Nakashima, Yutaka Kanda, Masami Hamano, Shun-ichi Ikeda, Yuko Uosaki, Yoko Takata, Junji Kanazawa
-
Patent number: 6080771Abstract: DC107 derivatives represented by formula (I) or pharmaceutically acceptable salts thereof which have antimicrobial activity and antitumor activity are provided: ##STR1## wherein R.sup.1 represents CO(CR.sup.4A R.sup.4B).sub.n1 (O(CH.sub.2).sub.p1).sub.n2 OR.sup.5 {wherein n1 represents an integer of 1 or 2; R.sup.4A and R.sup.4B are the same or different, and each represents hydrogen or lower alkyl; p1 and n2 each represents an integer of 1 to 10; and R.sup.Type: GrantFiled: August 13, 1998Date of Patent: June 27, 2000Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Yutaka Kanda, Hitoshi Arai, Hiroyuki Yamaguchi, Tadashi Ashizawa, Shun-ichi Ikeda, Chikara Murakata, Tatsuya Tamaoki
-
Patent number: 5981558Abstract: DC107 derivatives represented by formula (I) or pharmaceutically acceptable salts thereof which have antimicrobial activity and antitumor activity are provided: ##STR1## wherein R.sup.1 represents hydrogen, lower alkoxyalkyl, aralkyloxyalkyl, lower alkoxyalkoxyalkyl, lower alkoxyalkoxyalkoxyalkyl, aralkyl, tetrahydropyranyl, COR.sup.4, or the like; R.sup.2 represents hydrogen or COR.sup.6 ; R.sup.3 represents --CH.sub.2 OCOR.sup.7, phthalimidomethyl, or the like; and W represents oxygen or NR.sup.8 (wherein R.sup.8 represents hydroxy, lower alkoxy, lower alkenyloxy, aralkyloxy, substituted or unsubstituted arylsulfonylamino, or lower alkoxycarbonylamino).Type: GrantFiled: August 13, 1998Date of Patent: November 9, 1999Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Hitoshi Arai, Yutaka Kanda, Hiroyuki Yamaguchi, Tadashi Ashizawa, Chikara Murakata, Shun-ichi Ikeda, Tatsuya Tamaoki
-
Patent number: 5925641Abstract: The present invention relates to a farnesyltransferase inhibitor and an antitumor agent comprising, as an active ingredient, a piperazinedione derivative represented by formula (I): ##STR1## wherein R.sup.1 and R.sup.2 independently represent lower alkyl, lower alkoxyalkyl, substituted or unsubstituted aryl, or aralkyl; R.sup.3 and R.sup.4 independently represent mercapto, lower alkanoylthio, aroylthio, lower alkoxycarbonylthio, or aryloxycarbonylthio, or alternatively R.sup.3 and R.sup.4 are combined together to form disulfide; and R.sup.5 and R.sup.6 independently represent hydrogen, lower alkyl, lower alkoxyalkyl, hydroxyalkyl, lower alkanoyloxyalkyl, aroyloxyalkyl, aralkyloxyalkyl, or aralkyl.Type: GrantFiled: August 19, 1997Date of Patent: July 20, 1999Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Yutaka Kanda, Yutaka Saitoh, Kazuhito Akasaka, Tamio Mizukami, Hirofumi Nakano
-
Patent number: 5733924Abstract: DC107 derivatives represented by the formula (I): ##STR1## or pharmacologically acceptable slats thereof, ?wherein R.sup.1 is hydrogen, lower alkoxyalkyl, aralkyloxyalkyl, lower alkoxyalkoxyalkyl, lower alkoxyalkoxyalkoxyalkyl, aralkyl, tetrahydropyranyl, COR.sup.4 or the like; R.sup.2 represents hydrogen or COR.sup.5 ; R.sup.3 represents lower alkyl, lower alkenyl, aralkyl which may be substituted with substituted or unsubstituted aryl, lower alkoxyalkyl, aralkyloxyalkyl, substituted or unsubstituted aryloxyalkyl, lower alkoxycarbonylalkyl, lower alkanoyloxyalkyl, alicyclic alkanoyloxyalkyl or the like, or bonds to Y to represent a single bond; Y bonds to R.sup.3 to represent a single bond, or bonds to Z to represent a single bond; Z represents hydrogen or bonds to Y to represent a single bond; W represents oxygen or NR.sup.6, with the proviso that the compound wherein R.sup.1, R.sup.2 and Z each represents hydrogen, R.sup.3 bonds to Y to represent a single bond, and W represents oxygen (DC107) is excluded.Type: GrantFiled: April 17, 1997Date of Patent: March 31, 1998Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Yutaka Kanda, Yutaka Saitoh, Hiromitsu Saito, Tadashi Ashizawa, Kazuyo Sugiyama, Katsushige Gomi, Shingo Kakita, Yuichi Takahashi, Chikara Murakata
-
Patent number: 5728830Abstract: The present invention relates to a farnesyltransferase inhibitor and an antitumor agent comprising, as an active ingredient, a piperazinedione derivative represented by formula (I): ##STR1## wherein R.sup.1 and R.sup.2 independently represent lower alkyl, lower alkoxyalkyl, substituted or unsubstituted aryl, or aralkyl; R.sup.3 and R.sup.4 independently represent mercapto, lower alkanoylthio, aroylthio, lower alkoxycarbonylthio, or aryloxycarbonylthio, or alternatively R.sup.3 and R.sup.4 are combined together to form disulfide; and R.sup.5 and R.sup.6 independently represent hydrogen, lower alkyl, lower alkoxyalkyl, hydroxyalkyl, lower alkanoyloxyalkyl, aroyloxyalkyl, aralkyloxyalkyl, or aralkyl.Type: GrantFiled: May 22, 1995Date of Patent: March 17, 1998Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Yutaka Kanda, Yutaka Saitoh, Kazuhito Akasaka, Tamio Mizukami, Hirofumi Nakano
-
Patent number: 5334611Abstract: Novel mitomycin derivatives represented by the formula (I) are obtained by introducing a substituent at the 6-position. The mitomycin derivatives of the present invention have an antitumor activity.Type: GrantFiled: August 3, 1993Date of Patent: August 2, 1994Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Hitoshi Arai, Yutaka Kanda, Motomichi Kono, Masaji Kasai, Tadashi Ashizawa, Katsushige Gomi
-
Patent number: 5256685Abstract: Novel mitomycin derivatives represented by the formula (I) are obtained by introducing a substituent at the 6-position. The mitomycin derivatives of the present invention have an antitumor activity.Type: GrantFiled: March 26, 1992Date of Patent: October 26, 1993Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Hitoshi Arai, Yutaka Kanda, Motomichi Kono, Masaji Kasai, Tadashi Ashizawa, Katsushige Gomi
-
Patent number: 5187186Abstract: DC-88A derivatives represented by the general formula: ##STR1## wherein X represents hydrogen or CO.sub.2 R.sup.1 (in which R.sup.1 represents hydrogen, a straight-chain or branched alkyl having 1 to 4 carbon atoms, allyl, or benzyl); and ##STR2## have an excellent anti-tumor activity and are useful as anti-tumor agents.Type: GrantFiled: September 6, 1991Date of Patent: February 16, 1993Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Yutaka Kanda, Youichi Uosaki, Hiromitsu Saito, Hiroshi Sano, Eiji Kobayashi, Makoto Morimoto, Satoru Nagamura
-
Patent number: 5117006Abstract: A DC-88A derivative represented by general formula: ##STR1## wherein ##STR2## represents ##STR3## has an excellent antitumor activity and is useful as an anti-tumor agent.Type: GrantFiled: May 15, 1991Date of Patent: May 26, 1992Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Hiromitsu Saito, Masaji Kasai, Makoto Morimoto, Eiji Kobayashi, Yoichi Uosaki, Yutaka Kanda, Hiroshi Sano